Co-Founder & Managing Director
Mr. Dyett is a Founder of Salem Partners and Salem Partners Wealth Management. Mr. Dyett heads the firm's efforts in the Life Sciences. He has raised in excess of $500 million of equity and completed multiple merger and acquisition assignments for Salem Partners' clients. Mr. Dyett helped raise several rounds of venture capital for Adams Respiratory Therapeutics which was purchased for $2.3 billion by Reckitt Benckiser in 2008. Recently, Mr. Dyett helped launch ZS Pharma, a specialty pharmaceutical company focused on developing non-absorbed drugs for renal, cardiovascular, liver and metabolic diseases. Salem raised several rounds of venture capital and participated in each round as a principal investor. ZS Pharma completed a successful initial public offering in June 2014 and was subsequently purchased by AstraZeneca plc for $2.7 billion. Mr. Dyett serves on the investment committee of Salem Partners Wealth Management. Prior to founding Salem Partners, Mr. Dyett was a banker with Gerard Klauer Mattison & Co., Inc. and Needham and Co., Inc. Mr. Dyett serves on the Board of Directors of Femasys, Inc. and the Sierra Total Return Fund and serves as an advisor to Akashi Therapeutics. Mr. Dyett also serves on the Board of Trustees of Middlesex School in Concord, MA. Mr. Dyett is a graduate of Harvard College.
email John at email@example.com